Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > BioSante Reports Product Development Highlights

November 10th, 2005

BioSante Reports Product Development Highlights

Abstract:
"We achieved milestones across our key clinical programs this quarter. We presented positive Phase III data for Bio-E-Gel(TM), licensed three patents that cover the use of testosterone (LibiGel(TM)) to treat hypoactive sexual desire disorder in women on hormone contraception, and entered into an allergy licensing option agreement for our CaP nanotechnology," said Stephen M. Simes, BioSante's president and chief executive officer.

Source:
businesswire

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Products

Spectradyne Partners with Particle Technology Labs for Measurement Services December 6th, 2018

Mode-Changing MEMS Accelerometer from STMicroelectronics Combines High Measurement Resolution and Ultra-Low Power for Industrial Applications November 7th, 2018

Fat-Repellent Nanolayers Can Make Oven Cleaning Easier October 17th, 2018

Aculon, Inc. Enters into Strategic Partnership Agreement with Henkel Corporation to Supply Key Mobile Device Manufacturers with NanoProof® PCB Waterproof Technology October 17th, 2018

Profiles

Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011

Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011

Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010

Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010

Announcements

New organic molecule shatters phosphorescence efficiency records and paves way for rare metal-free applications July 5th, 2024

Single atoms show their true color July 5th, 2024

New method cracked for high-capacity, secure quantum communication July 5th, 2024

Searching for dark matter with the coldest quantum detectors in the world July 5th, 2024

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project